has been indicated that the clinical efficacy of 5ARI relative to placebo is seen after a minimum treatment duration of at least 6 to 12 months [3] . The effects of finasteride on prostate size have been studied extensively, with maximal reduction of prostate volume achieved within 6 months [4] . In addition to this complaint, the authors did not evaluate the effects of α-blocker and 5ARI alone in the treatment of the patients with MetS. As we mentioned above, the effects of α-blocker and 5ARI on the symptoms of patients with lower urinary tract symptoms, especially with MetS, differ.
In conclusion, the treatment of BPH in patients with MetS should differ from that in patients without MetS. The pathophysiology of BPH includes hyperinsulinemia, which contributes to an increase in prostate smooth muscle tone via increased activation of the sympathetic system, and increased estradiol levels and a decreased testosterone/ estradiol balance due to increased aromatase levels. In addition, the clinical effects of 5ARIs are seen after a minimum treatment duration of at least 6 to 12 months. However, hypercortisolism, which plays an important role in the development of MetS, may arise from inhibition of 5α-reductase. Therefore, whereas the use of 5ARI improves BPH, it can be a cause of aggravation of MetS. For these reasons, patients with MetS and BPH should be treated with α-blockers as a first-line treatment.
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